IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer

Podobne knjige/članki

• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  od: Shang-Gin Wu, et al.
  Izdano: (2017-07-01)
• The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
  od: Wu, Shang-Gin, et al.
  Izdano: (2016)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  od: Wu, Shang-Gin, et al.
  Izdano: (2017)
• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
  od: Wu, Shang-Gin, et al.
  Izdano: (2016)
• miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
  od: Liu, Yi-Nan, et al.
  Izdano: (2020)